Retinitis Pigmentosa News and Research RSS Feed - Retinitis Pigmentosa News and Research

Retinitis pigmentosa (RP) is the name given to a group of inherited eye diseases that affect the retina (the light-sensitive part of the eye). RP causes the breakdown of photoreceptor cells (cells in the retina that detect light). Photoreceptor cells capture and process light helping us to see. As these cells breakdown and die, patients experience progressive vision loss. The most common feature of all forms of RP is a gradual breakdown of rods (retinal cells that detect dim light) and cones (retinal cells that detect light and color). Most forms of RP first cause the breakdown of rod cells. These forms of RP, sometimes called rod-cone dystrophy, usually begin with night blindness. Night blindness is somewhat like the experience normally sighted individuals encounter when entering a dark movie theatre on a bright, sunny day. However, patients with RP cannot adjust well to dark and dimly lit environments.
NanoScope awarded AGI Grant to re-sensitize photo-degenerated retinal areas with MCO

NanoScope awarded AGI Grant to re-sensitize photo-degenerated retinal areas with MCO

Millions of individuals affected by Retinitis Pigmentosa (RP) are visually impaired due to photo-degeneration of retina. The visual loss starts with the peripheral region progressing towards the center leading to tunnel vision. Currently, there is no cure to restore vision in these patients. The disease leads not only to physical impairment, but has a significant emotional and psychological impact on quality of life of patients as well as their family members. [More]
Research opens way towards making promising advances in retinal prostheses

Research opens way towards making promising advances in retinal prostheses

A major therapeutic challenge, the retinal prostheses that have been under development during the past ten years can enable some blind subjects to perceive light signals, but the image thus restored is still far from being clear. [More]
Interim results from clinical trial demonstrate safety of cell-based therapy for retinitis pigmentosa

Interim results from clinical trial demonstrate safety of cell-based therapy for retinitis pigmentosa

Regenerative medicine company jCyte and the Sue & Bill Gross Stem Cell Research Center at the University of California, Irvine report that their investigational therapy for retinitis pigmentosa (RP) has demonstrated a favorable safety and tolerability profile in an ongoing Phase I/II clinical trial. [More]
Shire’s Xiidra receives FDA approval for treating dry eye disease in adult patients

Shire’s Xiidra receives FDA approval for treating dry eye disease in adult patients

Shire plc announces that the U.S. Food and Drug Administration has approved Xiidra (lifitegrast ophthalmic solution) 5%, a twice-daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease in adult patients. [More]
Pain reliever appears to help preserve vision in animal model of retinal degeneration

Pain reliever appears to help preserve vision in animal model of retinal degeneration

A pain medicine that potently activates a receptor vital to a healthy retina appears to help preserve vision in a model of severe retinal degeneration, scientists report. [More]
New study suggests how rod photoreceptors may have originated to give rise to nocturnal mammals

New study suggests how rod photoreceptors may have originated to give rise to nocturnal mammals

Retinas from our earliest vertebrate ancestors had cone-like photoreceptors, presumably allowing them to see in daylight, but little ability to see at night. Then, millions of years ago in the Mesozoic era, and in relatively short order, mammals emerged that had retinas with predominantly rod photoreceptors, allowing for them to see at night perhaps to hunt for food while their dinosaur predators were dozing. [More]
LALES study analyzes risk, prevalence of early and late stage AMD among Latinos

LALES study analyzes risk, prevalence of early and late stage AMD among Latinos

The University of Southern California Roski Eye Institute researchers and clinicians published results of the largest population-based study of adult Latinos and age-related macular degeneration (AMD) in the National Eye Institute-funded "Los Angeles Latino Eye Study." The study, published in JAMA Ophthalmology, is the first to analyze the risk and prevalence of early and late stage AMD and its impact on quality of life for older Latinos. [More]
Pioneering gene therapy may lead to potential cure for common causes of vision loss

Pioneering gene therapy may lead to potential cure for common causes of vision loss

Pioneering gene therapy has restored some vision to patients with a rare form of genetic blindness for as long as four years, raising hopes it could be used to cure common causes of vision loss, new University of Oxford research published today shows. [More]
University’s blindness therapy comes a step closer following landmark licensing deal with US firm

University’s blindness therapy comes a step closer following landmark licensing deal with US firm

Hundreds of thousands of people worldwide, who have a disease that can lead to blindness, could have their sight restored after The University of Manchester entered into a technology license with Seattle-based company Acucela Inc. [More]
University's blindness therapy comes a step closer following landmark licensing deal with US firm

University's blindness therapy comes a step closer following landmark licensing deal with US firm

Hundreds of thousands of people worldwide, who have a disease that can lead to blindness, could have their sight restored after The University of Manchester entered into a technology license with Seattle-based company Acucela Inc. [More]
Leading entrepreneurs, innovators to take part in Royal Society of Medicine's 12th Medical Innovations Summit

Leading entrepreneurs, innovators to take part in Royal Society of Medicine's 12th Medical Innovations Summit

A group of leading entrepreneurs and innovators will be gathering at the Royal Society of Medicine on Saturday 16 April to take part in the Society’s 12th Medical Innovations Summit. Providing a twice-yearly platform for the presentation and discussion of inspirational ideas and developments in the field of medicine and healthcare, the Summits encourage innovators at the very beginning of their careers, as well as established clinicians and academics. [More]

Retina Implant receives CE approval for latest Alpha AMS device

Retina Implant AG, the leading developer of subretinal implants for patients blinded by retinitis pigmentosa (RP), today announced it received CE approval of its Alpha AMS device for marketing in the European economic area. [More]
Amarantus BioScience Holdings closes $3M investment

Amarantus BioScience Holdings closes $3M investment

Amarantus BioScience Holdings, Inc., a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan diseases, today announced the closing of a $3M investment from an institutional investor. Under the terms of the agreement, the investor will be issued $3.3M worth of Series H Convertible Preferred Stock (including 10% original issue discount) from the Company and five year warrants exercisable for 13,200,000 shares of common stock at $0.40 per share. [More]
Study reveals another clue to workings of trachoma

Study reveals another clue to workings of trachoma

Another clue to the workings of trachoma - the world's leading infectious cause of blindness - has been revealed in a new study published in BMC Infectious Diseases. Researchers identified markers of genetic regulation present in the early stages of infection that could predispose children to developing the condition in its long-term, severe form. [More]
CUMC, Iowa scientists use CRISPR to repair genetic mutation responsible for retinitis pigmentosa

CUMC, Iowa scientists use CRISPR to repair genetic mutation responsible for retinitis pigmentosa

Columbia University Medical Center and University of Iowa scientists have used a new gene-editing technology called CRISPR, to repair a genetic mutation responsible for retinitis pigmentosa (RP), an inherited condition that causes the retina to degrade and leads to blindness in at least 1.5 million cases worldwide. [More]
Shire announces resubmission of lifitegrast NDA to FDA for treatment of dry eye disease in adults

Shire announces resubmission of lifitegrast NDA to FDA for treatment of dry eye disease in adults

Shire plc today announced it has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration for its investigational candidate, lifitegrast, for the treatment of signs and symptoms of dry eye disease in adults. Shire resubmitted the NDA in response to the complete response letter (CRL) the company received from the FDA on October 16, 2015. [More]
Incidence of childhood myopia has more than doubled over last 50 years among American children

Incidence of childhood myopia has more than doubled over last 50 years among American children

The largest study of childhood eye diseases ever undertaken in the U.S. confirms that the incidence of childhood myopia among American children has more than doubled over the last 50 years. The findings echo a troubling trend among adults and children in Asia, where 90 percent or more of the population have been diagnosed with myopia, up from 10 to 20 percent 60 years ago. [More]
New gene editing technique could hinder retinal degeneration in rats with inherited blindness

New gene editing technique could hinder retinal degeneration in rats with inherited blindness

A new technique that has the potential to treat inherited diseases by removing genetic defects has been shown for the first time to hinder retinal degeneration in rats with a type of inherited blindness, according to a Cedars-Sinai study. [More]
Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

The Dompé biopharmaceutical company announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has officially designated recombinant human Nerve Growth Factor (rhNGF) - the investigational biotech molecule developed by Dompé based on research by Nobel Laureate Rita Levi Montalcini - as an orphan drug for the treatment of neurotrophic keratitis. [More]
Nightstar announces $35 million Series B financing round

Nightstar announces $35 million Series B financing round

NightstaRx Ltd, a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, announces a $35 million Series B financing round. The round was led by New Enterprise Associates, one of the world's leading venture capital firms. [More]
Advertisement
Advertisement